Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTERACT-PLUS
2024-512318-16-00Phase 2Authorised
- Sponsor
- Erasmus MC
- Start
- Oct 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan, oxaliplatin, fluorouracil, folinic acid and bevacizumab in colorectal cancer (CRC), sponsored by Erasmus MC. Primary endpoint: Completion of all trial treatments. Planned start Oct 2024; status: authorised.
02
Drugs
irinotecanoxaliplatinfluorouracilfolinic acidbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-512318-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512318-16-00.